target audience: TECH BUYER Publication date: Nov 2024 - Document type: IDC MarketScape - Doc Document number: # US52713224
IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment
Content
List of Tables
List of Figures
Get More
When you purchase this document, the purchase price can be applied to the cost of an annual subscription, giving you access to more research for your investment.
Related Links
Abstract
This IDC study focuses on technology solutions and consulting services in the life science R&D DCT space. This document is a qualitative and quantitative assessment based on criteria that should be important to life science companies when considering the selection of a DCT technology solutions and consulting services provider. This is the first time that an IDC MarketScape assessment of both DCT technology solutions and consulting services in life science R&D has been performed.
"Call them what you may, DCTs, virtual trials, hybrid trials (95% of DCTs are hybrid trials), modern trials, digital trials, and so on and so forth, DCTs are here to stay. The hype has gone down, and caution has quietly crept in. The focus is on integration, integration of technologies, integration of touch points to create unified and meaningful experiences, and the alignment of technologies and operating models. It is about moving beyond the how to the why. It is about focusing on 'patient centricity,' generating evidence, and measuring outcomes. The way the industry is perceiving DCTs is maturing. No, DCTs aren't going away. Instead, DCTs are becoming a 'business as usual' strategy today," said Dr. Nimita Limaye, research VP, Life Science R&D Strategy and Technology.